New study tests best way to use firsekibart to stop gout attacks
NCT ID NCT07616531
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether taking Firsekibart regularly (every 4 weeks) is better than using it only when a gout flare starts. It involves 118 adults who had no flares during 24 weeks of initial treatment. The goal is to see which approach prevents more gout attacks over the next 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Firsekibart (a drug injected under the skin)
What this could lead to
If successful, this could show that taking Firsekibart on a regular schedule is better than waiting for a flare to use it, helping prevent gout attacks.
What could go wrong
This is a small, early-stage trial with only 118 participants, so results may not apply to everyone. The drug may cause side effects, and the study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT FLARES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changxin People's Hospital
Huzhou, China
Contact Phone: •••-•••-••••
-
Fuzhou University Affiliated Provincial Hospital
Fuzhou, China
Contact Phone: •••-•••-••••
-
Jinhua Municipal Central Hospital
Jinhua, China
Contact Phone: •••-•••-••••
-
Ningbo Medical Center Lihuili Hospital
Ningbo, China
Contact Phone: •••-•••-••••
-
The First People's Hospital of Wenlin
Wenzhou, China
Contact Phone: •••-•••-••••
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
Contact Phone: •••-•••-••••
-
The Second Affiliated Hospital of Zhejiang Chinese Medical University
Hangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tongde Hospital of Zhejiang Province
Hangzhou, China
Contact
-
Zhejiang Hospital
Hangzhou, China
Contact Phone: •••-•••-••••
-
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Contact Phone: •••-•••-••••